Polypoidal Choroidal Vasculopathy vs. Typical Wet AMD: What Patients Need to Know
What Is Polypoidal Choroidal Vasculopathy?
PCV is a condition that affects the vascular tissue beneath the retina. Understanding its defining features helps explain why it requires a different diagnostic and treatment approach than typical wet AMD.
PCV is characterized by an abnormal network of branching blood vessels within the choroid, which is the vascular layer that sits just beneath the retina. At the ends of these branching vessels, small balloon-like dilations called polyps develop. These polypoidal lesions are the hallmark of the condition and are responsible for its name.
These polyps can leak a mix of fluid and blood beneath the retina, leading to serous or hemorrhagic detachments of the retinal pigment epithelium (the supportive cell layer between the retina and choroid). In some cases, the polyps can rupture and cause a sudden bleed under the central retina, which may result in rapid, significant vision loss. PCV tends to affect the macular region and the area around the optic nerve, and its activity can fluctuate over time.
Both conditions involve abnormal blood vessels affecting the macula, but the underlying biology is different. In typical wet AMD, new blood vessels grow from the choroid through a thin membrane called Bruch's membrane, driven largely by a protein called vascular endothelial growth factor (VEGF). In PCV, the problem lies within the inner choroid itself, where abnormal branching vessels with polypoidal dilations develop rather than new vessels pushing through Bruch's membrane.
PCV is also closely associated with a pattern called the pachychoroid phenotype, meaning the choroid is abnormally thickened with enlarged underlying vessels. Patients with PCV also tend to present at a younger average age than those with typical wet AMD, and the condition has a different epidemiological profile overall.
PCV has a distinct patient profile compared to typical wet AMD. It is significantly more common in people of Asian and African descent, where it accounts for a larger share of exudative macular disease diagnoses. Men may be affected more frequently than women with PCV, while typical wet AMD shows a more balanced or slightly female-predominant distribution.
Known risk factors for PCV include high blood pressure, smoking, and certain genetic variants that partially overlap with those linked to AMD. Because PCV disproportionately affects certain ethnic groups, our retina specialists keep it in mind when evaluating any patient with signs of exudative macular disease, regardless of age or background.
How PCV Is Diagnosed
Accurate diagnosis of PCV requires specialized imaging. Because PCV and typical wet AMD can look similar on routine examination, our specialists use a combination of advanced imaging tools to identify the features that distinguish them.
Indocyanine green angiography (ICGA) has long been considered the most reliable method for diagnosing PCV. In this test, a dye called indocyanine green is injected into a vein, and a specialized camera captures images of the blood vessels beneath the retina as the dye circulates. This allows the branching vascular network and the polypoidal dilations to be seen clearly, often appearing as clusters of bright spots that are difficult to detect with standard fluorescein angiography.
ICGA remains an important diagnostic tool, especially when the distinction between PCV and typical wet AMD influences the choice of treatment.
Optical coherence tomography (OCT) uses light waves to produce detailed cross-sectional images of the retina and the tissue beneath it. This noninvasive scan plays a central role in evaluating both PCV and typical wet AMD. In PCV, OCT often shows sharp, dome-shaped elevations of the retinal pigment epithelium where the polyps are located, as well as a pattern called the double-layer sign that reflects the branching vascular network underneath.
Enhanced depth imaging OCT, a variation of this technology, provides better visualization of the choroid and can reveal the choroidal thickening and enlarged underlying vessels associated with the pachychoroid phenotype that is characteristic of PCV.
OCT angiography (OCTA) is a newer, noninvasive imaging technique that maps blood flow in the retinal and choroidal layers without requiring a dye injection. It can identify the branching vascular network characteristic of PCV and may detect polypoidal lesions in many cases. Because it does not require dye, it is well tolerated and useful for monitoring over time.
However, OCTA has limitations in imaging deeper choroidal structures and may not detect all polyps as reliably as ICGA. Our specialists often use OCTA for screening and follow-up, reserving ICGA for cases where definitive polyp identification is needed to guide treatment decisions.
Treatment Options for PCV
The treatment of PCV differs meaningfully from typical wet AMD. While anti-VEGF injections are a cornerstone of care for both conditions, PCV often requires additional treatment to fully address the polypoidal lesions. Our retina specialists will recommend a plan based on your specific imaging findings and disease characteristics.
Anti-VEGF medications are injected into the eye and work by blocking the protein that drives abnormal blood vessel growth and leakage. These injections are effective at reducing fluid and stabilizing or improving vision in patients with PCV, just as they are in typical wet AMD. However, anti-VEGF therapy alone may be less effective at achieving complete closure of the polypoidal lesions compared to its effect on the neovascular activity seen in typical wet AMD.
When polyps remain active after anti-VEGF treatment, continued leakage and recurrent fluid can occur, often requiring sustained frequent injections. Anti-VEGF monotherapy may still be appropriate for certain patients, particularly when the polyps are located in areas where photodynamic therapy carries greater risk.
Verteporfin photodynamic therapy (PDT) has a uniquely important role in treating PCV. In this procedure, a light-sensitive medication called verteporfin is injected intravenously. It accumulates in the abnormal blood vessels, including the polypoidal lesions. A non-thermal laser is then applied to the treatment area, activating the verteporfin and selectively damaging the abnormal vessels while sparing surrounding tissue.
PDT is particularly effective at inducing closure of the polyps, which is a key goal in achieving long-term disease control with PCV. While PDT is now used less often for typical wet AMD in the current era of anti-VEGF therapy, it remains a meaningful treatment specifically for PCV.
The combination of anti-VEGF injections and verteporfin PDT has become a preferred treatment approach for many patients with PCV. The rationale is straightforward: anti-VEGF injections control leakage and vascular permeability, while PDT directly targets the polypoidal lesions to cause regression. Studies examining randomized controlled trials have shown that combination therapy achieves significantly higher rates of complete polyp regression compared to anti-VEGF treatment alone.
By addressing both components of the disease together, combination therapy may provide more durable control and reduce the frequency of ongoing injections over time. Your retina specialist will determine whether this approach is appropriate based on the location, size, and activity of your polyps.
Newer anti-VEGF agents with extended dosing intervals, including faricimab and high-dose aflibercept, are being studied and used in the management of PCV. These medications may allow longer intervals between treatment visits while still maintaining disease control. Faricimab targets two pathways (VEGF-A and angiopoietin-2), and research is ongoing to determine whether this dual mechanism offers additional benefits in PCV specifically.
As the evidence evolves, our specialists stay current with the latest treatment approaches so that patients receive care that reflects the best available options.
Living with PCV and Managing It Long-Term
PCV is a long-term condition that requires ongoing monitoring and, in many cases, retreatment over time. Understanding what to expect helps patients stay engaged in their care and respond quickly when changes occur.
Patients who receive combination therapy with PDT and anti-VEGF injections may experience periods of disease stability with reduced injection frequency after successful polyp regression. This outcome differs from typical wet AMD, where ongoing regular injections are usually required indefinitely. However, PCV can recur, and new polyps may develop over time, making continued follow-up essential.
Some patients also experience episodes of sudden hemorrhage that require prompt evaluation. Long-term studies suggest that patients who maintain regular monitoring and receive timely retreatment when needed can achieve favorable visual outcomes.
Regular follow-up visits with your retina specialist are essential for detecting recurrent disease activity before it causes significant harm. OCT imaging is used routinely to check for fluid and structural changes, and ICGA may be repeated periodically to assess the status of the polypoidal lesions when reactivation is suspected. The interval between visits is individualized based on your current disease status and treatment history.
In addition to in-office monitoring, patients are encouraged to check their vision at home using an Amsler grid, a simple checkerboard-style chart used to detect distortion or blurring in the central visual field. Any new distortion, blurring, or sudden decrease in vision should be reported to your specialist promptly, without waiting for a scheduled appointment.
Frequently Asked Questions
These questions address common points of confusion about PCV and offer practical guidance for patients navigating diagnosis and treatment.
The distinction often cannot be made from a routine examination or a single imaging test alone. Indocyanine green angiography is typically the most definitive study for identifying the polypoidal lesions that define PCV, while OCT provides supporting structural clues such as sharp pigment epithelial elevations and choroidal thickening. If your imaging shows features that suggest PCV, your retina specialist may recommend ICGA even if it was not part of your initial workup, because identifying the polyps directly influences which treatments will be most effective for you.
The relationship between PCV and AMD has been debated among retinal specialists for years. PCV has traditionally been considered a subtype of neovascular (wet) AMD because both involve abnormal blood vessels affecting the macula. However, PCV has a distinct set of characteristics, including its association with the pachychoroid phenotype, its epidemiological pattern, and its different treatment response, that set it apart from typical choroidal neovascularization in AMD. For patients, the most important takeaway is that PCV requires specific diagnostic attention and may benefit from a treatment approach that differs from what is used for typical wet AMD.
Yes, PCV can occur in both eyes, though it is less likely to be bilateral compared to typical wet AMD. When PCV is active in one eye, your retina specialist will also monitor the other eye carefully for early signs of the condition, such as choroidal thickening or subtle vascular changes. Even if your second eye appears unaffected, regular monitoring of both eyes is an important part of ongoing care. Catching early changes in the fellow eye before symptoms develop gives the best opportunity for timely treatment.
Anti-VEGF injections are very effective at reducing leakage and fluid, but they do not always fully close the polyps themselves. When polyps remain open and active despite injections, they can continue to leak or bleed over time, making it difficult to maintain stable vision without very frequent injections. Photodynamic therapy targets the polyps directly to cause them to close, which can lead to more durable control. Your retina specialist will evaluate your imaging at each visit to determine whether adding PDT to your treatment plan could improve your long-term outcome.
Any sudden change in your central vision should be evaluated promptly. This includes a rapid increase in blurriness, new distortion when looking at straight lines, a dark spot appearing in your central field, or a sudden large decrease in vision. These symptoms can indicate that a polyp has bled or that there is a significant increase in fluid beneath the retina. PCV carries a higher risk of sudden submacular hemorrhage than typical wet AMD, so acting quickly when new symptoms develop is particularly important. Do not wait for your next scheduled appointment if you notice these changes.
Not necessarily. One of the potential advantages of PCV over typical wet AMD is that successful treatment with photodynamic therapy, either alone or in combination with anti-VEGF injections, can sometimes achieve polyp regression durable enough to allow extended intervals between treatments, or even a period free from active treatment. However, PCV can recur, and some patients do require long-term management. Your treatment schedule will be adjusted based on how well your disease responds and whether monitoring shows signs of returning activity.
Expert Retina Care at Rhode Island Eye Institute
Our retina specialists at Rhode Island Eye Institute are experienced in diagnosing and managing complex macular conditions like PCV, using advanced imaging and the latest treatment approaches to protect your vision. We take time to explain your diagnosis clearly and work with you to build a treatment plan that fits your needs. If you have been told you may have PCV or wet AMD, or if you are experiencing changes in your central vision, we encourage you to schedule a comprehensive evaluation with our team.